Inherited antithrombin deficiency: A review

Haemophilia

Volumn 14, Issue 6, 2008, Pages 1229-1239

  Patnaik, M M ^a   Moll, Stephan ^b  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Anticoagulant; Antithrombin; Deep vein thrombosis; Pulmonary embolism; Thrombin; Thrombosis

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBIN; ANTITHROMBIN CONCENTRATE; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; ASPARAGINASE; FONDAPARINUX; HEPARIN; HIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; OXYGEN; RECOMBINANT ANTITHROMBIN; THROMBIN INHIBITOR; UNCLASSIFIED DRUG;

ABNORMAL LABORATORY RESULT; ANTICOAGULATION; ANTIGENICITY; ANTITHROMBIN DEFICIENCY; ANTITHROMBIN TYPE 1 DEFICIENCY; ANTITHROMBIN TYPE 2 DEFICIENCY; ARTERY THROMBOSIS; AUTOSOMAL DOMINANT DISORDER; BLOOD CLOTTING FACTOR DEFICIENCY; CLINICAL FEATURE; COMPRESSION GARMENT; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DRUG DOSE INCREASE; DRUG HALF LIFE; FAMILIAL DISEASE; FETUS WASTAGE; GENETIC ANALYSIS; GENETIC ASSOCIATION; HUMAN; LOADING DRUG DOSE; LONG TERM CARE; MOLECULAR DYNAMICS; NONHUMAN; PATHOPHYSIOLOGY; POSTOPERATIVE HEMORRHAGE; PREGNANCY COMPLICATION; PRENATAL CARE; PREVALENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; THROMBOSIS PREVENTION; UNSPECIFIED SIDE EFFECT; VENOUS THROMBOEMBOLISM;

AGED; ANTICOAGULANTS; ANTITHROMBIN III; ANTITHROMBIN III DEFICIENCY; BLOOD COAGULATION; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; MUTATION; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; PREGNANCY OUTCOME; RECURRENCE; RISK FACTORS; THROMBOPHILIA; VENOUS THROMBOEMBOLISM;

EID: 55949104988     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2008.01830.x     Document Type: Review

References (33)

1. Li W, Johnson DJ, Esmon CT, Huntington JA. Structure of the antithrombin-thrombin-heparin ternary complex reveals the antithrombotic mechanism of heparin. Nat Struct Mol Biol 2004; 11: 857-62.
2. Johnson DJ, Langdown J, Li W, Luis SA, Baglin TP, Huntington JA. Crystal structure of monomeric native antithrombin reveals a novel reactive center loop conformation. J Biol Chem 2006; 281: 35478-86.
3. Tait RC, Walker ID, Perry DJ et al. Prevalence of antithrombin deficiency in the healthy population. Br J Haematol 1994; 87: 106-12.
4. Wells PS, Blajchman MA, Henderson P et al. Prevalence of antithrombin deficiency in healthy blood donors: A cross-sectional study. Am J Hematol 1994; 45: 321-4.
5. Finazzi G, Caccia R, Barbui T. Different prevalence of thromboembolism in the subtypes of congenital antithrombin III deficiency: Review of 404 cases. Thromb Haemost 1987; 18: 1094.
6. Tait RC, Walker ID, Islam SI et al. Influence of demographic factors on antithrombin III activity in a healthy population. Br J Haematol 1993; 84: 476-80.
7. Lane DA, Bayston T, Olds RJ et al. Antithrombin mutation database: 2nd (1997) update. For the Plasma Coagulation Inhibitors Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 1997; 77: 197-211.
8. Crowther MA, Kelton JG. Congenital thrombophilic states associated with venous thrombosis: A qualitative overview and proposed classification system. Ann Intern Med 2003; 138: 128-34.
9. Kottke-Marchant K, Duncan A. Antithrombin deficiency: Issues in laboratory diagnosis. Arch Pathol Lab Med 2002; 126: 1326-36.
10. Walker ID, Greaves I, Preston PE. Guideline: Investigation and management of heritable thrombophilia. Br J Haematol 2001; 114: 512-28.
11. Maclean PS, Tait RC. Hereditary and acquired antithrombin deficiency: epidemiology, pathogenesis and treatment options. Drugs 2007; 67: 1429-40.
12. Vossen CY, Conard J, Fontcuberta J et al. Risk of a first venous thrombotic event in carriers of a familial thrombophilic defect. The European Prospective Cohort on Thrombophilia (EPCOT). J Thromb Haemost 2005; 3: 459-64.
13. Martinelli I, Mannucci PM, De Stefano V et al. Different risks of thrombosis in four coagulation defects associated with inherited thrombophilia: A study of 150 families. Blood 1998; 92: 2353-8.
14. Bucciarelli P, Rosendaal FR, Tripodi A et al. Risk of venous thromboembolism and clinical manifestations in carriers of antithrombin, protein C, protein S deficiency, or activated protein C resistance: A multicenter collaborative family study. Arterioscl Thromb Vasc Biol 1999; 19: 1026-33.
15. Robertson L, Wu O, Langhorne P et al. Thrombophilia in pregnancy: A systematic review. Br J Haematol 2006; 132: 171-96.
16. Vicente V, Rodriguez C, Soto I, Fernandez M, Moraleda JM. Risk of thrombosis during pregnancy and post-partum in hereditary thrombophilia. Am J Hematol 1994; 46: 151-2.
17. Preston FE, Rosendaal FR, Walker ID et al. Increased fetal loss in women with heritable thrombophilia. Lancet 1996; 348: 913-6.
18. Vossen CY, Preston FE, Conard J et al. Hereditary thrombophilia and fetal loss: A prospective follow-up study. J Thromb Haemost 2004; 2: 592-6.
19. Ungerstedt JS, Schulman S, Egberg N, Antovic J, Blomback N. Discrepancy between antithrombin activity methods revealed in Antithrombin Stockholm: Do factor Xa-based methods overestimate antithrombin activity in some patients? Blood 2002; 99: 2271-2.
20. McColl M, Tait RC, Walker ID, Perry DJ, McCall F, Conkie JA. Low thrombosis rate seen in blood donors and their relatives with inherited deficiencies of antithrombin and protein C: Correlation with type of defect, family history, and absence of the factor V Leiden mutation. Blood Coagul Fibrinolysis 1996; 7: 689-94.
21. Demers C, Ginsberg JS, Hirsh J, Henderson P, Blajchman MA. Thrombosis in antithrombin-III-deficient persons: Report of a large kindred and literature review. Ann Intern Med 1992; 116: 754-61.
22. Mateo J, Oliver A, Borrell M, Sala N, Fontcuberta J. Increased risk of venous thrombosis in carriers of natural anticoagulant deficiencies. Results of the family studies of the Spanish Multicenter Study on Thrombophilia (EMET study). Blood Coagul Fibrinolysis 1998; 9: 71-8.
23. Bauersachs R, Alban S. Perioperative bridging with fondaparinux in a woman with antithrombin deficiency. Thromb Haemost 2007; 97: 498-9.
24. Konkle BA, Bauer KA, Weinstein R, Greist A, Holmes HE, Bonfiglio J. Use of recombinant human antithrombin in patients with congenital antithrombin deficiency undergoing surgical procedures. Transfusion 2003; 43: 390-4.
25. Schulman S, Tengborn L. Treatment of venous thromboembolism in patients with congenital deficiency of antithrombin III. Thromb Haemost 1992; 68: 634-6.
26. van den Belt AG, Sanson BJ, Simioni P et al. Recurrence of venous thromboembolism in patients with familial thrombophilia. Arch Intern Med 1997; 157: 2227-32.
27. Buller HR, Agnelli G, Hull RD, Hyers TM, Prins MH, Raskob GE. Antithrombotic therapy for venous thromboembolic disease: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 401-28S.
28. Yamada T, Yamada H, Morikawa M et al. Management of pregnancy with congenital antithrombin III deficiency: Two case reports and a review of the literature. J Obstet Gynaecol Res 2001; 27: 189-97.
29. Bates SM, Greer IA, Pabinger I, Sofaer S, Hirsh J. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physician Guidelines (8th edition). Chest 2008; 133: 844-86.
30. Schwartz RS, Bauer KA, Rosenberg RD et al. Clinical experience with antithrombin III concentrate in treatment of congenital and acquired deficiency of antithrombin. Am J Med 1989; 87(Suppl. 3B): 53-60S.
31. Menache D, O'Malley JP, Schorr JB et al. Evaluation of the safety, recovery, half-life, and clinical efficacy of antithrombin III (human) in patients with hereditary antithrombin III deficiency. Blood 1990; 75: 33-9.
32. Edmunds T, Van Patten SM, Pollock J et al. Transgenically produced human antithrombin: Structural and functional comparison to human plasma-derived antithrombin. Blood 1998; 91: 4561-71.
33. Kearon C, Kahn SR, Agnelli G, Goldhaber S, Rascob GE, Comerota AJ. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physician Guidelines (8th edition). Chest 2008; 133: 454-545.